Meeting
2017 ASCO Annual Meeting
Neoadjuvant chemotherapy with mFOLFOXIRI alone for cT4 and fixed cT3 rectal cancer: Results from a single arm phase II study (FORTUNE).
Authors
Jianwei Zhang
Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
Jianwei Zhang , Yue Cai , Huabin Hu , Dianke Chen , Jian Xiao , Jiayu Ling , Wang Wenjing , Ping Lan , Lei Wang , Meijin Huang , Xiaojian Wu , Liang Kang , Jianping Wang , Yanhong Deng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT02217020
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3607)
DOI
10.1200/JCO.2017.35.15_suppl.3607
Abstract #
3607
Poster Bd #
230
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
The efficacy of neoadjuvant treatment in locally advanced rectal cancer with dMMR.
First Author: Yanhong Deng
Poster
2016 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy alone with mFOLFOXIRI in locally advanced rectal cancer: A single-arm phase II study.
First Author: Yanhong Deng
Poster
2023 ASCO Annual Meeting
Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.
First Author: Pooja Karukonda
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang